



Prometheus Diagnostic Services Sheet

IBD	PROMETHEUS® IBD sgi Diagnostic™ #1800 The first and only test that combines serologic, genetic and inflammation markers in a proprietary Smart Diagnostic Algorithm to provide added IBD diagnostic clarity. This test will help physicians differentiate IBD vs. non-IBD and CD vs. UC in one comprehensive blood test.
	PROMETHEUS® Crohn's Prognostic #2001 Provides personalized serogenetic profile for each patient that quantifies their risk of developing complications over time.
ANTI-TNF MONITORING	PROMETHEUS® Anser™ IFX #3150 A new generation quantitative laboratory test that allows healthcare providers to measure and monitor serum IFX and ATI concentrations at anytime during therapy. Incorporating drug monitoring may clarify what factors may be contributing to a patient's loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action.
	PROMETHEUS® Anser™ ADA #3170 A next generation quantitative monitoring assay that allows healthcare providers to measure and monitor serum adalimumab (ADA) drug levels and antibodies to adalimumab (ATA) levels at any time during therapy to help clarify what factors are contributing to a patient's loss of response; drug clearance or immunogenicity.
CELIAC	PROMETHEUS® Celiac PLUS #6360 The most comprehensive test for celiac disease. Combines both the PROMETHEUS® Celiac Genetics & PROMETHEUS® Celiac Serology.
	PROMETHEUS® Celiac Genetics #6260 Analyzes a patient's genetic profile for genes specifically associated with celiac disease. Advanced high-resolution DNA probe analysis of HLA-DQ Haplotypes allow for disease risk stratification depending upon which HLA genes are detected.
	PROMETHEUS® Celiac Serology #1155 A comprehensive serum antibody profile which includes deamidated gliadin IgA & IgG, anti-endomysial (EMA) IgA, anti-tissue transglutaminase IgA and total serum IgA.
THIOPURINE MANAGEMENT	PROMETHEUS® TPMT Genetics #3300 Helps classify patients as one of three genotypes allowing physicians to individualize dosing, identify patients in whom thiopurine therapy should be avoided, and help reduce the risk of leukopenia.
	PROMETHEUS® TPMT Enzyme #3320 Provides a quantitative analysis of a patient's thiopurine methyltransferase (TPMT) enzyme activity level allowing physicians to individualize dosing, identify patients in whom thiopurine therapy should be avoided, and help reduce the risk of leukopenia.
	PROMETHEUS® Thiopurine Metabolites #3200 Testing assists physicians in optimizing ongoing dosing of thiopurine immunosuppressant therapy to reach and maintain therapeutic goal. Thiopurine metabolite testing also helps to identify drug metabolite levels that may lead to toxicity and some of the reasons for treatment failure.
ADDITIONAL TESTS	PROMETHEUS® FIBROSpect® II #4000 Testing can aid physicians in differentiating no/mild liver fibrosis from moderate-to-severe liver fibrosis in patients with hepatitis C, and may help reduce the number of liver biopsies required.
	PROMETHEUS® LactoTYPE® #6100 A genetics test to identify genetic variant C/T-13910 which is highly associated with adult-type hypolactasia. Testing assists physicians with stratifying patients with suspected lactose intolerance into those with a genetic predisposition and those whose underlying cause may be due to other disease potentially requiring further diagnostic workup.

Assays and methods within these tests may be covered by one or more US pending or issued patents. For details please visit www.prometheuslabs.com. PROMETHEUS, For the person in every patient, the Link Design, LactoTYPE, FIBROSpect, and Anser are trademarks or registered trademarks of Socié

te des Produits Nestlé

é S.A. Vevey, Switzerland

05/2014

A Nestlé Health Science Company